Lenacapavir is a twice-yearly injection that can prevent HIV infections. New licensing deals with Gilead and Indian manufacturers mean it will be available in 120 low- and middle-income countries at about US$40 a year.
The Gates Foundation will help Hetero with funding and volume guarantees and says it invested more than US$80 million to speed production. Dr. Reddy’s will receive help from the Clinton Health Access Initiative, Unitaid and Wits RHI to supply generics from 2027 at the same price. Campaigners warn some middle-income countries are excluded and that money is also needed for awareness, training and supply.
Difficult words
- drug — A substance used for medical treatment.
- injection — A shot given using a needle.
- countries — Nations or areas with their own governments.
- access — The ability to use or reach something.
- funding — Money provided for a specific purpose.
- healthcare — Services related to health and medical care.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is lenacapavir considered a major step in fighting HIV?
- How do you think funding can improve healthcare services?
- What might happen if middle-income countries are excluded from access?
Related articles
People learn to use robotic leg prostheses but misjudge their gait
A four-day study found that people who practised with a robotic lower‑limb prosthesis improved their walking but misjudged their own movement. Researchers say better visual feedback could help users calibrate their body image and gait.
Toxic cosmetics sold in Latin American street markets
Informal markets in Latin America sell cosmetics often without labels or health checks. Studies found toxic metals in many cheap products; authorities seized counterfeit goods and experts warn of health risks, especially for children.
